Drugmaker GlaxoSmithKline (GSK)’s chief executive officer Andrew Witty on Tuesday unveiled the company’s plans to allow “free access to its library of 13,500 potential malaria treatments and devote the profits from its experimental [RTS,S] vaccine to battling tropical illnesses that beset poor countries,” Bloomberg reports (Randall, 1/20).
Scientists have identified a group of proteins they say could form the basis of a malaria vaccine, Australia’s ABC News reports. “However, they say more laboratory work and clinical trials need to be done, with a vaccine at least 10 years away,” the news service reports (Macey, 1/19).
Though H1N1 (swine flu) activity worldwide has slowed, the potential of a new wave of infections in the northern hemisphere in late winter or early spring remains viable, Keiji Fukuda, the WHO’s top flu expert, said Monday at the start of the WHO’s weeklong Executive Board meeting, Reuters reports. The H1N1 pandemic “initially sparked widespread concern about antiviral and vaccine supplies, especially in developing countries, but many nations have cut back their vaccine orders recently because the pandemic has not turned out as deadly as originally feared,” the news service writes (Nebehay, 1/18).
Also In Global Health News: HIV Vaccine; Chile To Provide Free ‘Emergency Contraception’; China Indoor Smoking Ban; Malaria Clinical Trials
TIME Examines HIV Vaccine Efforts TIME features a profile on David Ho, director of the Aaron Diamond AIDS Research Center (ADARC) in New York City, who is currently working on a novel HIV vaccine. Ho “now believes that a traditional shot, one that relies on snippets of a virus to…
Lancet Series Papers Examine Surveillance, Economic Impact Of NTDs “As national programmes respond to the new opportunities presented for scaling up preventive chemotherapy programmes for the coadministration of drugs to target [several neglected tropical diseases (NTDs)] possible synergies between existing disease-specific policies and protocols need to be examined,” write the…
Keiji Fukuda, the special adviser to the WHO director general on pandemic influenza, on Thursday dismissed allegations that the agency exaggerated the threat of the H1N1 (swine flu) pandemic and has been influenced by the pharmaceutical industry, the Washington Post reports. Fukuda’s defense came amid reports this week that the Council of Europe will investigate the WHO’s actions and as several countries slash H1N1 vaccine orders.
Amid recent complaints that the WHO exaggerated the threat of the H1N1 (swine flu) virus, the agency announced Tuesday an upcoming independent review of the agency’s handling of the pandemic, Agence France-Presse reports (1/12).
A $27 million UNICEF program that aims to decrease disease-related child deaths in West Africa did not meet its goal of reducing death rates by at least 25 percent at the conclusion of 2006, according to a Lancet study published on Tuesday, the Associated Press reports. “The U.N. children’s agency pursued strategies like vaccinating children, giving them vitamin A pills and distributing bednets to protect against malaria from 2001 to 2005 in parts of 11 countries,” according to the article.
Media Outlets Examine U.S. Plans For Leftover H1N1 Vaccine, Efforts To Keep Flu Vaccine Production On Track
After working to ensure the U.S. had access to enough H1N1 (swine flu) vaccine, health officials may now face a new dilemma â€“ a vaccine surplus, the Associated Press reports. “Get ready for a huge flu-shot push as health officials try to rekindle interest in protection against this new influenza strain that, despite plummeting cases, still is threatening lives â€“ even as they reassess just how much more vaccine needs to be shipped,” the news service writes.
Also In Global Health News: Dengue Vaccine; Medicines For Poor; Gates New Ag Development Director; USDA Efforts In Afghanistan; Soccer And Malaria
Experimental Dengue Vaccine Shows Promise In Clinical Trial Of Adults An experimental dengue vaccine created by the drugmaker Sanofi-Aventis protected a group of healthy adults from all four strains of the virus, “bringing the drugmaker closer to providing the first vaccine against a disease that threatens 40 percent of the…